FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour By Ogkologos - April 4, 2025 703 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MOTION study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR El cáncer en mi comunidad: Ampliar el acceso a las pruebas... September 1, 2020 Study Probes Awareness of Alcohol’s Link to Cancer January 18, 2023 Spring Budget 2023: What does it mean for the mission to... March 15, 2023 Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other... September 4, 2018 Load more HOT NEWS NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared... The digital shift: How are remote GP appointments affecting cancer patients? Neoadjuvant Toripalimab Combined with Axitinib Demonstrates a Promising Pathologic Response Rate... Introducing our new podcast for researchers
